This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group
study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV
events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects
with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial
infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including
those managed with percutaneous coronary intervention (PCI) or medically managed.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.